Difference between revisions of "Balsalazide"

From Self-sufficiency
Jump to: navigation, search
 
m (1 revision)
 
(No difference)

Latest revision as of 12:12, 20 September 2010

Balsalazide
File:Balsalazide.png
Systematic (IUPAC) name
(E)-5-([4-(2-carboxyethylcarbamoyl)phenyl]diazenyl)-2-hydroxybenzoic acid
Clinical data
Pregnancy
category
  • US: B (No risk in non-human studies)
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability <1%
Protein binding ≥99%
Biological half-life 12hr
Identifiers
CAS Number 80573-04-2
ATC code A07EC04 (WHO)
PubChem CID 5362070
DrugBank APRD00141
ChemSpider 10662422
Chemical data
Formula C17H15N3O6
Molar mass 357.318 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Balsalazide is an anti-inflammatory drug used in the treatment of inflammatory bowel disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK. It is also sold in generic form in the US by several generic manufacturers.

It is usually administered as the disodium salt.

Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA,[1] in the large intestine. Its advantage over that drug in the treatment of ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
Intestinal anti-infectives
Intestinal adsorbents
Antipropulsives (opioids)
Opium (Laudanum) · Codeine · Morphine (Paregoric)

crosses BBB: Diphenoxylate · Difenoxin

does not cross BBB: Loperamide
Intestinal anti-inflammatory agents
Antidiarrheal micro-organisms
Other antidiarrheals
  1. ↑ Kruis, W; Schreiber, I; Theuer; Brandes; Schütz; Howaldt; Krakamp; Hämling; Mönnikes (2001). "Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses". Gut. 49 (6): 783–9. doi:10.1136/gut.49.6.783. PMC 1728533 Freely accessible. PMID 11709512.  More than one of |author2= and |last2= specified (help); More than one of |author3= and |last3= specified (help); More than one of |author4= and |last4= specified (help); More than one of |author5= and |last5= specified (help); More than one of |author6= and |last6= specified (help); More than one of |author7= and |last7= specified (help); More than one of |author8= and |last8= specified (help); More than one of |author9= and |last9= specified (help) edit
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Balsalazide&oldid=32792"